Interview with Ryan Zimmerman, Managing Director and Medical Technology Analyst, BTIG and former Director of Surgery at ...

To start things off, I understand Vaxart is researching oral vaccines for COVID-19, norovirus, and influenza. Could you give us an overview of each program and where they are in the development ...

For readers who are not familiar with SINTX, give us a brief overview of the company and how it evolved into what it is today. Mr. Olson: SINTX was founded on the use of silicon nitride ceramic ...

Recently you wrote a wonderful article that was published in Forbes magazine. In the context of an introduction to your coverage, what inspired you to write that piece, and what are some of the main ...

How did the last year play out for your coverage, and what do you see going forward? Are you optimistic? Dr. Nierengarten: Yes, I am optimistic. The reasons are based on what we saw happening last ...

So it’s been a few years since we last spoke. Let’s start with a brief overview and history of the company. Dr. Itescu: Sure. So Mesoblast has been publicly listed both on Nasdaq and the Australian ...

Tell us about the current trends and themes that are most impacting the space, the subsectors, you watch? Dr. Phipps: Sure. My coverage spans a range of biopharma companies, including large-caps such ...

Tell us briefly about Picard Medical and the history of SynCardia Total Artificial Heart. Mr. Schnegelsberg: Let me start with SynCardia and then go to Picard. SynCardia is a company with a long ...

Matthew DeCicco, CFA, is Director of Equities and a Portfolio Manager for Lord Abbett & Co. He is responsible for directing Lord Abbett’s equity investment activities, including portfolio management ...